Updated:
Livzon Mabpharm
Livzon Mabpharm operates as the biologics arm of Livzon Pharmaceutical Group, a publicly traded Chinese pharmaceutical company (SZSE: 000513).
Livzon Mabpharm
Livzon Mabpharm operates as the biologics arm of Livzon Pharmaceutical Group, a publicly traded Chinese pharmaceutical company (SZSE: 000513). The company was founded to spearhead the group's foray into monoclonal antibodies and biosimilar development, with a facility in Zhuhai, Guangdong. Its wealth origin traces to Livzon Group's broader pharmaceutical operations. The firm's strategy centers on developing biosimilars of established biologic drugs, such as rituximab and bevacizumab, alongside novel monoclonal antibodies for oncology and autoimmune diseases. Its pipeline includes both internally discovered candidates and licensed assets for the Chinese market. Geographic focus is primarily China, with an office in New York suggesting intent for global regulatory pathways or partnerships. Scale details are limited in the public record. The company employs an undisclosed number of scientists and support staff at its Zhuhai R&D and manufacturing campus. In 2023, Livzon Mabpharm's parent reported progress in its biosimilar pipeline during its annual earnings, per the firm's official communications. The New York office implies outreach to Western investors or collaborators. As a subsidiary of a listed parent, Livzon Mabpharm is structurally distinct from venture-backed biotechs — its funding flows from Livzon Group's pharmaceutical cash flows. This provides operational stability but also ties the firm to corporate strategic priorities rather than standalone investor timelines.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Zhuhai
Corporate office
Zhuhai, Guangdong, China
Additional offices
New York, United States
Frequently asked questions
Who runs investment decisions at Livzon Mabpharm?
Livzon Mabpharm is a subsidiary of Livzon Pharmaceutical Group, a publicly traded company. Its strategic direction is set by the parent group's leadership, though specific executives for the Mabpharm unit are not consistently disclosed in public filings (per Livzon Group's annual reports).
Is Livzon Mabpharm structured as a single family office or does it operate more like a venture firm?
Livzon Mabpharm is a corporate R&D and manufacturing subsidiary of Livzon Pharmaceutical Group, not a family office or venture firm. It operates within the parent company's pharmaceutical business model, focusing on biologic drug development and commercialization (public record).
What investment stages does Livzon Mabpharm typically target?
Livzon Mabpharm does not function as an investment firm; it is a biotechnology company. Its activities are product-stage oriented, from preclinical discovery through clinical trials and regulatory approval, primarily in China (per the firm's pipeline disclosures).
Which sectors does Livzon Mabpharm explicitly avoid?
Livzon Mabpharm focuses narrowly on monoclonal antibodies and biosimilars for oncology and autoimmune diseases, based on its publicly disclosed pipeline. No explicit avoidance policy is stated, but it has not publicly ventured into other therapeutic areas like vaccines or gene therapy (public record).
Where does the underlying wealth come from?
The firm is a subsidiary of Livzon Pharmaceutical Group, a publicly traded company on the Shenzhen Stock Exchange. Its funding originates from the parent group's pharmaceutical revenues, not from a disclosed family or individual fortune (public record).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: